Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study

Andrew Alexis, Ali Moiin, Jill Waibel, Paul Wallace, David Cohen, Vivian Laquer, Pearl Kwong, Amber Reck Atwater, Christopher Schuster, Jennifer Proper, Maria Silk, Evangeline Pierce, Sreekumar Pillai, Maria Jose Rueda, Angela Moore, Unknown

Open source

DOI: 10.1007/s40257-025-00970-8
Published: 2025-07-15
Container: American Journal of Clinical Dermatology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40257-025-00970-8,
  title = {Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study},
  author = {Andrew Alexis and Ali Moiin and Jill Waibel and Paul Wallace and David Cohen and Vivian Laquer and Pearl Kwong and Amber Reck Atwater and Christopher Schuster and Jennifer Proper and Maria Silk and Evangeline Pierce and Sreekumar Pillai and Maria Jose Rueda and Angela Moore and Unknown},
  year = {2025},
  journal = {American Journal of Clinical Dermatology},
  doi = {10.1007/s40257-025-00970-8},
  url = {https://doi.org/10.1007/s40257-025-00970-8}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study
AU  - Andrew Alexis
AU  - Ali Moiin
AU  - Jill Waibel
AU  - Paul Wallace
AU  - David Cohen
AU  - Vivian Laquer
AU  - Pearl Kwong
AU  - Amber Reck Atwater
AU  - Christopher Schuster
AU  - Jennifer Proper
AU  - Maria Silk
AU  - Evangeline Pierce
AU  - Sreekumar Pillai
AU  - Maria Jose Rueda
AU  - Angela Moore
AU  - Unknown
PY  - 2025
JO  - American Journal of Clinical Dermatology
DO  - 10.1007/s40257-025-00970-8
UR  - https://doi.org/10.1007/s40257-025-00970-8
ER  -

APA

Alexis, A., Moiin, A., Waibel, J., Wallace, P., Cohen, D., Laquer, V., Kwong, P., Atwater, A. R., Schuster, C., Proper, J., Silk, M., Pierce, E., Pillai, S., Rueda, M. J., Moore, A., & Unknown (2025). Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-025-00970-8

Source records

crossref · retrieved 2026-09-26T10:08:15.426Z